Chardan analyst Keay Nakae downgraded Korro Bio (KRRO) to Neutral from Buy with a $7 price target The firm views the negative Phase I/IIa REWRITE trial evaluating KRRO-110 as a “significant setback” for the company. It will require new human clinical data, which now is in 2027, to rebuild investor confidence in Korro’s OPERA design platform, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: